FDA-Approved Drug May Enhance Immunotherapy Against Rare Liver Cancer

Researchers at the University of Washington have found that a drug already approved by the FDA may enhance the effectiveness of immunotherapy against fibrolamellar carcinoma, a rare type of liver cancer that has not responded well to checkpoint inhibitors. This discovery offers a potential new treatment avenue for patients with limited options.

The study, while focused on fibrolamellar carcinoma, highlights the broader potential of repurposing existing drugs to overcome resistance to immunotherapy. Checkpoint inhibitors have revolutionized cancer treatment, but many tumors, including fibrolamellar carcinoma, evade these therapies. The University of Washington team identified that the FDA-approved drug works by modulating the tumor microenvironment, making cancer cells more susceptible to immune attack.

Other cancers are also receiving significant research attention. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are exploring innovative approaches to immunotherapy. Calidi Biotherapeutics focuses on developing stem cell-based platforms to deliver therapeutic agents directly to tumors, potentially overcoming resistance mechanisms similar to those seen in fibrolamellar carcinoma.

The implications of this research are far-reaching. If the findings are confirmed in clinical trials, patients with fibrolamellar carcinoma could gain access to a treatment that combines an already available drug with immunotherapy, potentially improving outcomes. Moreover, the approach of repurposing existing drugs could accelerate the development of effective combination therapies for other hard-to-treat cancers.

BioMedWire, a platform covering developments in biotechnology and life sciences, reported on this breakthrough. BioMedWire is part of the Dynamic Brand Portfolio @IBN, which provides services including press release distribution and social media amplification. For more information, visit BioMedWire. Full terms and disclaimers can be found here.